SCHEMBL23218504

SCHEMBL23218504

CCOC(=O)Cc1ccccc1OCc1coc2c(CN(C)CC3CC3)cc(Br)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.35
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CFD P00746 1/20 0.33
PKM P14618 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.32
ADRA2A P08913 1/20 0.32
MCHR1 Q99705 1/20 0.32
TP53 P04637 2/20 0.32
THRB P10828 1/20 0.32
SLC1A5 Q15758 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853104 1.00 TBXAS1 (0.35) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL28736131 0.90 CFD (0.38) CFDCCR5
SCHEMBL29852719 0.88 TBXAS1 (0.35) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL23218932 0.88 TBXAS1 (0.35) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL29592670 0.88 TBXAS1 (0.39) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL23218048 0.88 TBXAS1 (0.39) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL29853013 0.88 TBXAS1 (0.39) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL23218787 0.85 MEN1 (0.38) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL29852908 0.85 MEN1 (0.38) TBXAS1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL23218843 0.85 PIM1 (0.36) TBXAS1MAPTCFDPKMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885MAPT 4793/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885MAPT 3561/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.